RxDoctor Payments Data

Graeme Steele, MD

Urology · Boston, MANPI 1174573604

Payments from drug & device makers

$385in general payments, 2019–2025

Across 8 payments — averaging $48.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$290
  • Dentsply IH Inc.$43
  • AstraZeneca$35
  • Dentsply IH AB$17

What the payments were for

  • Food & beverage$6016%
  • Education$32584%

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$385 in reported general payments places this provider in the 25th percentile of 327 urology providers in Massachusetts.

See all urology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$521,945
Medicare patients
1,407
Services billed
3,863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron68$65,575
Tamsulosin Hcl603$10,248
Finasteride325$5,033
Oxybutynin Chloride ErOxybutynin Chloride77$2,744
Testosterone18$2,141
Methenamine Hippurate35$1,925
Estradiol13$1,920
Alfuzosin Hcl ErAlfuzosin Hcl35$1,085
Dutasteride19$989
NitrofurantoinNitrofurantoin Macrocrystal32$603
Oxybutynin Chloride22$551
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst51$416
Terazosin Hcl24$358
Testosterone Cypionate23$316
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl17$245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$290$65,57568 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 327 urology providers in Massachusetts.

Other urology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →